Table 1 Pharmacokinetic parameters for DMT based on non–compartmental analyses [geometric mean (95% CI), range].

From: Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants

 

0.6 mg/min

1.2 mg/min

1.8 mg/min

2.4 mg/min

Cmax (ng/ml)

26 (22–31)

51 (42–61)

78 (63–96)

105 (85–128)

 

13–46

23–88

20–149

24–174

Tmax (min)

86 (74–99)

102 (90–116)

96 (85–108)

96 (81–114)

 

40–120

50–120

50–120

40–120

t1/2α (min)

6.3 (5.6–7.2)

6.4 (5.7–7.2)

6.8 (6.1–7.6)

7.1 (6.1–8.3)

 

3.9–9.9

4.3–7.2

4.0–9.9

4.3–16

t1/2β (min)

19 (16–23)

18 (17–20)

18 (16–19)

18 (17–20)

 

9.8–44

14–26

13–29

14–24

CL (L/min)

34 (28–41)

36 (29–44)

34 (27–43)

32 (26–39)

 

20–78

18–106

17–158

19–132

Vz (L)

912 (704–1183)

941 (743–1192)

862 (663–1121)

832 (654–1058)

 

342–2047

373–2682

382–3346

466–3774

AUC∞ (ng*min/ml)

2153 (1767–2623)

4055 (3322–4950)

6342 (5043–7977)

9098 (7392–11199)

 

934–3592

1371–7905

1375–12409

2195–15249

Start time of t1/2β (min)

141 (139–144)

142 (140–145)

142 (139–144)

143 (141–145)

 

130–152

135–151

135–150

135–150

DMT concentration at the start of t1/2β (ng/ml)

2.0 (1.6–2.5)

3.6 (2.6–4.8)

6.5 (4.8–8.6)

9.0 (6.8–11.9)

 

0.82–6.9

1.05–10.9

2.1–18.7

2.9–19.9

  1. AUC area under the plasma concentration-time curve, AUC∞ AUC from time zero to infinity, CL apparent total clearance, Cmax maximum observed plasma concentration, t1/2α early elimination plasma half-life, t1/2β late elimination plasma half-life, Tmax time to reach Cmax, 95%CI 95% confidence interval, Vz apparent volume of distribution; n = 20.
Back to article page